Government
Houston, TX Fannin Innovation Studio announces its receipt of a $2,000,000 Phase II Small Business Innovation Research grant from the National Institute of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development for development of its ChorioAnchor device, in partnership with Texas Children’s Hospital, Baylor College of Medicine, and Texas A&M University
HHS stated that Gilead had “willfully and deliberately induced infringement of the HHS patents.” As a result, “Gilead has profited from research funded by hundreds of millions of taxpayer dollars and reaped billions from PrEP,” through the sale of Truvada and Descovy.
The division previously had three clinical divisions and one nonclinical division. Under the restructuring, it will six divisions, three for oncology.
A*STAR’s Institute of Bioengineering and Nanotechnology has teamed up with the Singapore Institute of Advanced Medicine Holdings Pte Ltd to explore how to better tackle nasopharyngeal carcinoma, a type of head and neck cancer, through targeted proton therapy.
Researchers with the National Institute on Aging published research of a gene variant, APO3 Christchurch (APOE3ch), that appears to confer resistance to Alzheimer’s disease.
Late Friday, President Donald Trump put forth Hahn’s name to take over the top spot of the nation’s regulatory agency.
An international team of researchers have put forward a position statement, published in Science, whichlays out a new healthcare framework to help aging populations stay healthier for longer.
A disappointed Merck said it was reviewing its options for a possible appeal, while a pleased Gilead said if an appeal came, it was confident a higher court would come to the same verdict as the federal appeals court.
As Nancy Pelosi’s drug pricing reform bill winds its way through the House toward an expected full vote in coming days, life sciences organizations are marshalling their forces in opposition to what they see as innovation-killing legislation.
The approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.
PRESS RELEASES